Jacksonville, Florida
Cancer clinical trials in Jacksonville, FL
189 cancer studies are recruiting participants at sites in Jacksonville as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Jacksonville at a glance
- 189 studies are recruiting at a site in Jacksonville.
- By phase: Early Phase 1 (1), Phase 1 (18), Phase 1/2 (28), Phase 2 (41), Phase 2/3 (8), Phase 3 (54), Phase 4 (2), No phase (13), Observational (24). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (111), university, hospital or other (70), government (8).
- By research area: Breast Cancer (56), Lung Cancer (44), Lymphoma (36), Prostate Cancer (22), Pancreatic Cancer (18), Melanoma (13).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Jacksonville
Basic details from each study's public record (the 30 most recently updated of 189). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- Mayo Clinic - Jacksonville
- Registry record
- NCT05696626 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT05564377 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic Hospital ( Site 0013)
- Registry record
- NCT06966700 · updated
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- ALX Oncology Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT07007559 · updated
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT05969860 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Mayo Clinic
- Registry record
- NCT05315700 · updated
A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
- Observational
- Ages 18 to 100
- All sexes
- Sponsor
- University of Florida
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT05655494 · updated
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Natera, Inc.
- Study site
- Baptist MD Anderson
- Registry record
- NCT07214532 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Lung cancer studies recruiting in Jacksonville
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NovoCure GmbH
- Study site
- Baptist MD Anderson Cancer Center, Baptist Health
- Registry record
- NCT06216301 · updated
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Mayo Clinic Florida
- Registry record
- NCT07277413 · updated
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT07063745 · updated
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- OSE Immunotherapeutics
- Study sites
- Cancer Specialists of North Florida - Northside · Cancer Specialists of North Florida - Riverside · Cancer Specialists of North Florida - Southpoint
- Registry record
- NCT06472245 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic in Florida ( Site 0014)
- Registry record
- NCT06312137 · updated
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07291037 · updated
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Jazz Pharmaceuticals
- Study site
- Cancer Specialists of North Florida
- Registry record
- NCT07459634 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Prostate cancer studies recruiting in Jacksonville
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT07073794 · updated
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Mayo Clinic Jacksonville
- Registry record
- NCT03972657 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Melanoma studies recruiting in Jacksonville
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT05136196 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Mayo Clinic Florida
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Lymphoma studies recruiting in Jacksonville
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT06724237 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Baptist MD Anderson Cancer Center ( Site 0176)
- Registry record
- NCT06890884 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Nemours Children's Clinic-Jacksonville
- Registry record
- NCT04546399 · updated
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT04840602 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mayo Clinic in Florida · Nemours Children's Clinic-Jacksonville
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT06337318 · updated
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Baptist Md Anderson Cancer Center
- Registry record
- NCT06846671 · updated
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Florida
- Registry record
- NCT06386315 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Jacksonville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Mayo Clinical Florida
- Registry record
- NCT07644559 · updated
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mayo Clinic Florida
- Registry record
- NCT07621718 · updated
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Mayo Clinic Florida
- Registry record
- NCT07805954 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Jacksonville, FL on ClinicalTrials.gov.
Ask about studies near Jacksonville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Florida
All Florida locations
706 studies recruiting across 90 cities.
Tampa
217 studies recruiting.
Miami
200 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections